4SCAR123

4SCAR123 is a fourth-generation chimeric antigen receptor (CAR) T-cell therapy targeting CD123, developed by the Shenzhen Geno-Immune Medical Institute. It is designed for the treatment of various hematological malignancies, including B-cell malignancies and acute myeloid leukemia. The therapy utilizes a lentiviral vector to engineer autologous T cells to express a CAR construct featuring CD28 and CD27 costimulatory domains, a CD3ζ signaling domain, and an inducible caspase 9 (iCasp9) safety switch. This safety switch allows for the rapid elimination of the CAR-T cells using a small molecule dimerizer in the event of severe adverse toxicities, such as cytokine release syndrome. In clinical settings for B-cell malignancies, 4SCAR123 is frequently evaluated in combination with other CAR-T products, such as 4SCAR19, to address antigen escape and reduce the risk of CD19-negative relapse.